Effective amyloid clearance with lecanemab in a female with Alzheimer's disease: A case report. (PubMed, Radiol Case Rep) - Sep 18, 2026 - "This case illustrates substantial amyloid clearance with preserved cognitive and functional status after 18 months of lecanemab treatment without treatment-related safety concerns. Continued lecanemab therapy beyond 18 months may be feasible in carefully selected patients with early-stage AD, although further real-world data are needed to establish its long-term benefits and risks."
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • CSF P-tau
|
|
Kenjiro Ono; Moeko Noguchi-Shinohara
|